Immix Biopharma Prices $150M Stock Offering, Diluting Shares by Over 30%
IMMX has more than doubled off its 52-week low of $1.87.
Summary
Immix Biopharma priced a $150 million underwritten public offering of 16.8 million shares of common stock at $8.94 per share. This substantial capital raise represents over 30% of the company's current market capitalization, leading to significant dilution for existing shareholders. The offering follows positive clinical trial results for its NXC-201 therapy, which showed a 95% complete response rate, announced earlier today. While the capital infusion provides financial runway, the magnitude of dilution is a critical factor for investors, especially given the company's previously reported increased cash burn in its Q1 2026 10-Q.
At the time of this announcement, IMMX was trading at $9.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $486.4M. The 52-week trading range was $1.87 to $11.61. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.